Pinney Associates
Private Company
Funding information not available
Overview
Pinney Associates is a privately held, US-based consulting firm founded in 1994, specializing in drug development and regulatory strategy, particularly for prescription-to-OTC switches, CNS-active drugs, and tobacco harm reduction. The firm provides high-level scientific and strategic services, acting as an extension of its clients' teams to navigate FDA and policy challenges. Its recent high-profile successes include key roles in the FDA approvals of OTC Opill and OTC RiVive, cementing its reputation as a leader in the public health-oriented switch space. The company operates on a fee-for-service business model, generating revenue from its consulting engagements.
Technology Platform
Integrated consulting methodology combining deep regulatory science, behavioral research, abuse liability assessment, and advanced data analytics to guide drug development and Rx-to-OTC switch programs.
Opportunities
Risk Factors
Competitive Landscape
Pinney Associates competes with other specialized regulatory consulting firms and the internal regulatory affairs departments of large pharma. Its key differentiator is its deep, published scientific expertise in niche areas like abuse liability, behavioral research for OTC switch, and tobacco harm reduction, combined with a track record of landmark approvals. It occupies a high-end, science-first segment of the market.